ACXP - Acurx Pharmaceuticals, Inc.
2.32
-0.040 -1.724%
Share volume: 82,870
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.15%
PREVIOUS CLOSE
CHG
CHG%
$2.36
-0.04
-0.02%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-14-2024 | 08-08-2024 | 11-12-2024 | 03-17-2025 | 05-12-2025 | 11-12-2025 | 03-12-2026 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 4.378 M | 4.122 M | 2.822 M | 2.782 M | 2.149 M | 2.029 M | 1.644 M | |
| Selling general and admin | 2.823 M | 2.296 M | 1.623 M | 1.957 M | 1.550 M | 1.599 M | 1.363 M | |
| Research and development | 1.555 M | 1.826 M | 1.198 M | 825.059 K | 598.798 K | 429.691 K | 281.807 K | |
| Total expenses | 4.378 M | 4.122 M | 2.822 M | 2.782 M | 2.149 M | 2.029 M | 1.644 M | |
| -5.85% | -31.54% | -1.41% | -22.74% | -5.61% | -18.94% | |||
| Operating income | -4.378 M | -4.122 M | -2.822 M | -2.782 M | -2.149 M | -2.029 M | -1.644 M | |
| Ebit | -4.378 M | -4.122 M | -2.822 M | -2.782 M | -2.149 M | -2.029 M | -1.644 M | |
| Pretax income | -4.378 M | -4.122 M | -2.822 M | -2.782 M | -2.149 M | -1.993 M | -1.578 M | |
| -5.85% | -31.54% | -1.41% | -22.74% | -7.28% | -20.80% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -4.378 M | -4.122 M | -2.822 M | -2.782 M | -2.149 M | -1.993 M | -1.578 M | |
| 5.85% | 31.54% | 1.41% | 22.74% | 7.28% | 20.80% |